Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totaling 26,560 shares, a decline of 60.5% from the June 30th total of 67,279 shares. Based on an average daily trading volume, of 70,934 shares, the short-interest ratio is currently 0.4 days. Approximately 1.6% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bone Biologics currently has an average rating of “Sell”.

Bone Biologics Trading Down 1.2%

NASDAQ:BBLG traded down $0.01 during trading hours on Wednesday, reaching $0.95. 3,073 shares of the company traded hands, compared to its average volume of 38,771. The business’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.32. Bone Biologics has a 1 year low of $0.94 and a 1 year high of $4.13. The stock has a market capitalization of $1.72 million, a P/E ratio of -0.42 and a beta of 0.90.

Bone Biologics (NASDAQ:BBLG) last released its earnings results on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). As a group, equities analysts anticipate that Bone Biologics will post -1.17 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC grew its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.